Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. (Q35022505)

5 August 2017

1 reference

title

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. (English)

1 reference

5 August 2017

Brian J Druker

1

0 references

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

21

1 reference

5 August 2017

issue

56

1 reference

5 August 2017

page(s)

8541-8546

1 reference

Tyrosine protein kinase inhibition and cancer.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

ARG tyrosine kinase activity is inhibited by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

Bcr-Abl inhibition as a modality of CML therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Protein kinase inhibitors: probes for the functions of protein phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Requirement for mast cell growth factor for primordial germ cell survival in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Psychogenic amenorrhea: Diagnosis by exclusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206081

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206081

1 reference

Dimensions Publication ID

5 August 2017

1027675129

0 references

1 reference